Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)

Drug Design, Development and Therapy

Volumn 9, Issue , 2014, Pages 155-161

  Navari, Rudolph M ^a,b,c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c South Bend Medical Services Corp   (United States)

Author keywords

5 HT3receptor antagonists; Chemotherapy induced nausea and vomiting; Netupitant; NK 1 receptor antagonists; Palonosetron

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CYTOCHROME P450 3A4; DEXAMETHASONE; FOSAPREPITANT; GRANISETRON; NETUPITANT; NETUPITANT PLUS PALONOSETRON; NEUROKININ 1 RECEPTOR; ONDANSETRON; PALONOSETRON; PLACEBO; ROLAPITANT; SEROTONIN 3 RECEPTOR; ISOQUINOLINE DERIVATIVE; NETUPITANT, PALOSENTRON DRUG COMBINATION; PYRIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE;

BINDING AFFINITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; HEADACHE; HUMAN; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; DOSE RESPONSE; DRUG ADMINISTRATION; NAUSEA; NEOPLASMS; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; ISOQUINOLINES; MOLECULAR STRUCTURE; NAUSEA; NEOPLASMS; PYRIDINES; QUINUCLIDINES; VOMITING;

EID: 84919694422     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S76158     Document Type: Review

References (50)

1. Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472–4478.
2. Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15(5): 497–503.
3. Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs. 2013;73:249–262.
4. Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol. 2010;6:1074–1084.
5. Navari RM. The current status of the use of palonosetron. Expert Opin Pharmacother. 2013;14:1281–1284.
6. Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs. 2009;69:1853–1858.
7. Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmcol. 2014;722:180–186.
8. Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009;28:1–7.
9. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9:188–195.
10. Navari RM. Treatment of chemotherapy-induced nausea. Community Oncol. 2012;9:20–26.
11. Stern RM, Koch KL, Andrews PLR. Nausea: Mechanisms and Management. New York, NY: Oxford University Press; 2011.
12. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(5):232–243.
13. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–4198.
14. NCCN Clinical Practice Guidelines in Oncology version 2. 2014; Anti-emesis. National Comprehensive Cancer Network (NCCN) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed July 8, 2014.
15. Navari RM. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014;15(17): 2599–2608.
16. Egler RM, Lee CH, Smith W, et al. Pharmacologic characterization of RS 25259-197, a novel and selective 5HT3 receptor antagonist in vivo. Br J Pharmacol. 1995;114:860–866.
17. Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety, and phar-macokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol. 2004;15:330–337.
18. Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010;626:193–199.
19. Botrel T, Clark O, Clark L, et al. Efficacy of palonosetron compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic treatment: systematic review and meta-analysis. Support Care Cancer. 2011;19:823–832.
20. Schwartzberg L, Barbour SY, Morrow GR, et al. Pooled analysis of phase III studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2014;22:469–477.
21. Popovic M, Warr DG, DeAngelis C, et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2014;22:1485–1497.
22. Boccia R, Grunberg S, Franco-Gonzales E, et al. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase III trial. Support Care Cancer. 2013;44:1453–1460.
23. Diemunsch P, Grelot L. Potential of substance P antagonists as anti-emetics. Drugs. 2000;60:533–546.
24. Sankhala KK, Pandya DM, Sarantopoulos J, et al. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Exp Opin Drug Metab Toxicol. 2009;12:1607–1614.
25. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol. 2003;1: 89–103.
26. Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer. 2006;14:354–360.
27. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from two randomized, double-blind, placebo controlled trials. Eur J Cancer. 2005;41(9):1278–1285.
28. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–2830.
29. Grote T, Hajdenberg J, Cartnell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol. 2006;4(8):403–408.
30. Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Exp Opin Investig Drugs. 2007;16:1977–1985.
31. Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol. 2007;47:834–840.
32. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol. 2011;29(11):1495–1501.
33. Poma A, Christensen J, Pertikis H, et al. Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 susbstrate. Support Care Cancer. 2013;21:S154. Abstract 441.
34. Rapoport BL, Poma A, Hedley ML, Martel RE, Navari RM. Phase III trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC) [abstract]. J Clin Oncol. 2014;32(Suppl 5):9638.
35. Schnadig ID, Modiano MR, Poma A, Hedley ML, Martel RE, Schwartzberg LS. Phase III trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC) [abstract]. J Clin Oncol. 2014;32(Suppl 5):9633.
36. Urban L, Poma A, Daqrdeno MM, Martel RE. Safety of rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) [abstract]. J Clin Oncol. 2014;32(Suppl 5):9636.
37. Rizzi A, Campi B, Camarda V, et al. In vitro and in vivo pharmacological characterization of the novel NK-1 receptor selective antagonist Netupitant. Peptides. 2012;37:86–97.
38. Rossi G, Tilkola SO, Rudengren C, et al. A positron emission tomography study to assess the degree of neurokinin-1 receptor occupancy in the human brain after single doses of netupitant to healthy male subjects [abstract]. J Clin Oncol. 2012;30(Suppl):9054.
39. Spinelli T, Calcagneli S, Giuliano C. Netupitant PET Imaging and ADME Studies in Humans. J Clin Pharm. 2014;54:97–108.
40. National Cancer Institute Drug Dictionary. Available from: http://www.cancer.gov/drug dictionary. Accessed October 15, 2014.
41. Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT3 tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684:1–7.
42. Stathis M, Pietra C, Rojas C, Slusher BS. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonose-tron exhibit synergistic effects. Eur J Pharmacol. 2012;689: 25–30.
43. Thomas AG, Stathis M, Rojas C, Slusher BS. Netupitant and palonose-tron trigger NK-1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014;232(8):2637–2644.
44. Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT3 and NK-1 receptor antagonists in prevention of emesis. Eur J Pharmacol. 2014;722:26–37.
45. Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25:1340–1346.
46. Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25:1328–1333.
47. Aapro M, Karthaus M, Schwartzberg LS, et al. Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy cycles [abstract]. J Clin Oncol. 2014;32(Suppl 5):9502.
48. Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25:1333–1339.
49. Schwartzberg L, Aapro M, Hesketh PJ, et al. do NK-1 receptor antagonists contribute to nausea control? Evaluation of the novel NEPA fixed-dose combination of NK-1 receptor antagonist plus a 5-HT3 receptor antagonist from pivotal trials. Support Care Cancer. 2014;22:S107. Abstract 161.
50. US Food and Drug Administration. FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy [press release]. Silver Springs, MD: US Food and Drug Administration; October 10, 2014. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements. Accessed October 10, 2014.